Panaji: Cancer patients in Goa and across India are set to receive significant financial relief as revised prices of several anti-cancer medicines came into effect on November 9, 2026. The price reduction follows a major decision by the National Pharmaceutical Pricing Authority (NPPA) to regulate trade margins on 137 identified non-scheduled anti-cancer medicines, making essential cancer treatments more affordable and accessible.

The initiative, introduced by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, aims to address excessive trade margins across the pharmaceutical supply chain. Under the new arrangement, trade margins on the identified medicines have been capped at 30% of their maximum retail price (MRP). Depending on the existing price structure, the revised MRPs are expected to bring substantial reductions in the cost of several cancer medicines.

According to official information released by the Government of India, the highest reported price reduction reached 96.45%, while the largest number of reductions fell within the 50% to 75% range. More than 650 formulations reportedly recorded price reductions exceeding 50%. As of November 9, 2026, 85 pharmaceutical companies had submitted revised MRPs covering 121 drugs and 1,366 stock-keeping units (SKUs).

The estimated annual savings from the revised prices stand at approximately ₹3,541 crore. This estimate is based on the difference between the earlier and revised prices applied to sales volumes recorded between April 2025 and March 2026.

Medicines Used in Different Cancer Treatments Included

The list of 137 identified medicines includes several important treatments used in oncology. These include immunotherapy drugs for more than 20 types of cancer, Denosumab used by certain breast and prostate cancer patients, Pegfilgrastim for preventing neutropenia, and Bevacizumab, which is approved for treating colon, ovarian and cervical cancers.

Widely used medicines such as Pembrolizumab, Durvalumab and Osimertinib are also covered under the initiative. The inclusion of these medicines is expected to improve affordability for patients who require specialised and often expensive treatment.

Implementation Across Pharmacies and Hospitals

The revised prices apply across the country, including Goa. Manufacturers are required to communicate updated prices to retailers and hospitals, publish revised price lists and ensure that the new MRPs are implemented. Retailers, dealers, hospitals and medical institutions are required to display the applicable revised prices.

Patients and consumers can verify the updated prices through the official NPPA website and the Pharma Sahi Daam mobile application. Checking the revised MRP can help patients ensure that they are not charged more than the applicable price.

The government has also emphasised the importance of maintaining existing production and supply levels to prevent shortages of notified medicines.

For cancer patients and their families in Goa, where treatment expenses can place considerable pressure on household finances, the revised pricing framework represents an important step towards improving access to affordable medicines. While the actual savings will depend on the specific medicine and treatment prescribed, the measure seeks to reduce unnecessary costs and make essential cancer therapies more accessible.

The initiative strengthens the broader objective of affordable healthcare by addressing medicine prices and supporting patients who depend on long-term and specialised cancer treatment.